Targeted Therapies Plus Chemotherapy Provide Path Around Acquired Resistance in AML
February 28th 2022Targeted therapies, specifically those agents directed at mutated proteins and aberrant protein-to-protein interactions, have been shown to improve survival among patients with relapsed or refractory acute myeloid leukemia.
Treatment and Sequencing Options Continue to Evolve in Relapsed/Refractory DLBCL
February 28th 2022The emergence of novel agents, including CAR T-cell therapies and antibody-drug conjugates, plus existing options such as chemoimmunotherapy and bone-marrow transplant, have combined to raise questions about the sequencing of these treatments in patients with diffuse large B-cell lymphoma.
Genotyping Offers Insights Into Key Characteristics of ALL Subtypes
March 2nd 2021Genomic sequencing is a critical step in informing the prognosis of patients with acute lymphoblastic leukemia and more information regarding specific subgroups of ALL, such as lineage ambiguous ALL, could pave the way for more personalized therapies for patients.
Armand Reviews Novel Therapeutics in Relapsed/Refractory Follicular Lymphoma
March 2nd 2021Although it is too soon to tell whether the addition of a CD20-directed antibody to novel agents in relapsed/refractory follicular lymphoma should become standard practice, it is clear that immunotherapy could represent the next paradigm shift.
BR Retains its Role in Frontline Waldenström Macroglobulinemia Despite the Utility of BTK Inhibitors
March 1st 2021The treatment landscape of Waldenström macroglobulinemia is becoming increasingly complex with second-generation BTK inhibitors; however, the combination of bendamustine and rituximab remains the frontline standard of care for this patient population.
Targeted Therapies Dominate the Relapsed/Refractory CLL Paradigm
February 27th 2021Targeted therapies have helped to improve responses in patients with relapsed chronic lymphocytic leukemia regardless of high-risk disease, although optimal sequencing and toxicity management need to be further explored to strengthen the utilization of these options.
Early Successes and Remaining Challenges of Harnessing Natural Killer Cells for Cancer Therapy
February 27th 2021Natural killer cells can offer several advantages over T cells for CAR therapy in that the former uses both a CAR dependent and independent mechanism for tumor eradication, has better safety, and off-the-shelf feasibility—all at a potentially lower cost.
Raising the Standard Beyond Frontline R-CHOP in DLBCL
February 26th 2021Rituximab plus CHOP is not a suitable frontline treatment regimen for all patients with diffuse large B-cell lymphoma, explained Andre H. Goy, MD, who specified that patients with a high-risk International Prognostic Index, elderly patients, and patients with high-risk molecular subtypes require alternative treatment.
Growing Body of Evidence Underscores the Activity and Safety of CAR T-cell Therapy in ALL
February 25th 2021Since the publication of the pivotal ELIANA trial in pediatric patients with acute lymphoblastic leukemia, the field of CAR T-cell therapy has grown significantly and left providers better equipped to understand and manage treatment-related adverse effects, such as cytokine release syndrome.
Deep Data Dive Needed for Upfront Treatment Selection in iNHL
February 29th 2020At the 24th Annual International Congress on Hematologic Malignancies®, Sonali M. Smith, MD, detailed the critical clinical trial findings currently informing treatment selection in the frontline indolent non-Hodgkin lymphoma paradigm.
Key AE Management Strategies in Place for CAR T-Cell Therapy in Hematologic Cancers
February 29th 2020With the main toxicities associated with CAR T-cell therapy being cytokine release syndrome and neurotoxicity, a multidisciplinary approach is vital to providing inclusive care to patients receiving this type of treatment.